Abstracts tagged "Eosinophilic Granulomatosus with Polyangiitis (Churg-Strauss)"

Abstract Number: 1610 • ACR Convergence 2025
Early Mepolizumab Initiation Enables High Glucocorticoid and Immunosuppressant Discontinuation Rates in EGPA: A Retrospective Cohort Study of 35 Patients
Takashi Yamane¹, Ayaka Inoue², Noriaki Yasuda², Takahisa Ohnishi³ and Akira Hashiramoto⁴, ¹Kakogawa Central City Hospital, Kobe, Hyogo, Japan, ²Kakogawa Central City Hospital, Kakogawa, Japan, ³Kakogawa Central City Hospital, Kobe, Japan, ⁴Department of Biophysics, Kobe University Graduate School of Health Sciences, Kobe, Japan
Background/Purpose: Mepolizumab (MPZ), an anti–interleukin-5 monoclonal antibody, has shown efficacy in reducing glucocorticoid (GC) dosage and sustaining remission in eosinophilic granulomatosis with polyangiitis (EGPA). This…
Abstract Number: 1608 • ACR Convergence 2025
Efficacy of Anti-IL-5/R Therapies on Specific Disease Manifestations of Eosinophilic Granulomatosis with Polyangiitis
Peter Merkel¹, Arnaud Bourdin², Bernhard Hellmich³, Nader Khalidi⁴, David Jackson⁵, David Jayne⁶, Parameswaran Nair⁷, Christian Pagnoux⁸, Ulrich Specks⁹, Benjamin Terrier¹⁰, Lena Börjesson Sjö¹¹, Priya Jain¹², Aadarsh Lal¹³, Sofia Necander¹⁴, Claire Walton¹⁵ and Michael Wechsler¹⁶, ¹University of Pennsylvania, Philadelphia, PA, ²Department of Respiratory Diseases, Montpellier University Hospitals, Arnaud de Villeneuve Hospital, Montpellier, France, ³Klinik für Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie, Medius Kliniken, Akademisches Lehrkrankenhaus der Universität Tübingen, Kirchheim unter Teck, Germany, ⁴Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, Canada, ⁵Guy’s Severe Asthma Centre, Guy's and St Thomas’ NHS Trust, London, and School of Immunology and Microbial Sciences, King's College London, London, United Kingdom, ⁶University of Cambridge, Cambridge, United Kingdom, ⁷Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, ON, Canada, ⁸Mount Sinai Hospital, University Health Network, Toronto, and Canadian Vasculitis Research Network (CanVasc), Toronto, ON, Canada, ⁹Mayo Clinic, Rochester, MN, ¹⁰Cochin Hospital, Paris, France, ¹¹Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca,, Gothenburg, Sweden, ¹²BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ¹³Respiratory & Immunology, AstraZeneca, Bengaluru, Karnataka, India, ¹⁴Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ¹⁵Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ¹⁶Department of Medicine, National Jewish Health, Denver
Background/Purpose: Results from the 1-year double-blind period and first year of the open-label extension (OLE) of the MANDARA trial (NCT04157348) demonstrated that over 60% of…
Abstract Number: 1605 • ACR Convergence 2025
Combined Anti-IL-5/IL-5R and Dupilumab Therapy in Eosinophilic Granulomatosis with Polyangiitis: A European Retrospective Study
Miriam Guerini¹, Pavel Novikov², Roberto Padoan³, Georgina Espigol-Frigole⁴, Jan Willem Cohen Tervaert⁵, Vincent Grobost⁶, Laurent Guilleminault⁷, Jan Walter Schroeder⁸, Bernhard Hellmich⁹, Joana Martins-Martinho¹⁰, Camillo Ribi¹¹, Mathieu Groh¹² and Benjamin Terrier¹³, ¹IRCCS Policlinico S. Matteo, University of Pavia, Pavia, Italy, ²Sechenov University, Moscow, Russia, ³University of Padova, Padova, Italy, ⁴Hospital Clínic de Barcelona, Barcelona, Spain, ⁵University of Alberta, Edmonton, AB, Canada, ⁶Internal medicine, CHU Clermont Ferrand Estaing, Clermont Ferrand, France, ⁷CHU Toulouse, Toulouse University, Toulouse, France, ⁸ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy, ⁹Klinik für Innere Medizin, Rheumatologie und Immunologie, medius Klinik Kirchheim, Kirchheim unter Teck, Germany, ¹⁰ULS Santa Maria, Lisbon, Portugal, ¹¹Lausanne University Hospital / University of Lausanne, Lausanne, Switzerland, ¹²Hôpital Foch, Suresnes, France, ¹³Cochin Hospital, Paris, France
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a small-vessel vasculitis characterized by asthma, ear, nose, and throat (ENT) symptoms, eosinophilia, and systemic involvement. Despite the…
Abstract Number: 1600 • ACR Convergence 2025
Real-world clinical effectiveness of Benralizumab for Eosinophilic Granulomatosis with Polyangiitis: a National multicenter study
Fabricio Benavides Villanueva¹, Andrea Tristan-Alonso², Carlos Martinez-Rivera³, Alicia Padilla-Galo⁴, Marina Blanco-Aparicio⁵ and Ricardo Blanco⁶, ¹Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Immunopathology Group,Santander, Spain, Santander, Spain, ²Division of Pneumology, Hospital Universitario Puerta del Hierro, Madrid, Spain, Majadahonda, Madrid, Spain, ³Division of Pneumology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, Barcelona, Catalonia, Spain, ⁴Division of Pneumology, Hospital Universitario Virgen de la Victoria, Málaga, Spain, Malaga, Andalucia, Spain, ⁵Division of Pneumology, Hospital Universitario A Coruña, A Coruña, Spain, A coruña, Galicia, Spain, ⁶Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Benralizumab is approved for eosinophil-driven conditions, like eosinophilic asthma. Recently, the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) authorized its…
Abstract Number: 1594 • ACR Convergence 2025
Two-Year Efficacy of Anti-Interleukin-5/Receptor Therapies According to Anti-Neutrophil Cytoplasmic Antibodies Status in Patients with Eosinophilic Granulomatosis with Polyangiitis
Benjamin Terrier¹, David Jayne², Bernhard Hellmich³, Nancy Agmon-Levin⁴, Parameswaran Nair⁵, Lena Börjesson Sjö⁶, Priya Jain⁷, Aadarsh Lal⁸, Sofia Necander⁹, Claire Walton¹⁰, Peter Merkel¹¹ and Michael Wechsler¹², ¹Cochin Hospital, Paris, France, ²University of Cambridge, Cambridge, United Kingdom, ³Klinik für Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie, Medius Kliniken, Akademisches Lehrkrankenhaus der Universität Tübingen, Kirchheim unter Teck, Germany, ⁴Clinical Immunology, Angioedema and Allergy, Sheba Medical Center, Ramat Gan, Israel, ⁵Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, ON, Canada, ⁶Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca,, Gothenburg, Sweden, ⁷BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ⁸Respiratory & Immunology, AstraZeneca, Bengaluru, Karnataka, India, ⁹Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ¹⁰Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ¹¹University of Pennsylvania, Philadelphia, PA, ¹²Department of Medicine, National Jewish Health, Denver
Background/Purpose: The MANDARA trial (NCT04157348) demonstrated that after two years of anti-interleukin-5/receptor (anti-IL-5/R) therapy over 60% of patients with relapsing or refractory eosinophilic granulomatosis with…
Abstract Number: 1592 • ACR Convergence 2025
Mepolizumab to Benralizumab Switch in Eosinophilic Granulomatosis with Polyangiitis (EGPA)
Adrien Cottu¹, Irene Mattioli², Xavier Puéchal³, Loic Guillevin⁴, Mathieu Groh⁵, Camille Taillé⁶, Maxime Samson⁷, Pascal Cathébras⁸, Halil Yildiz⁹, Grégory Pugnet¹⁰, Stéphane Jouneau¹¹, Marie-Charlotte Besse¹², François Lifermann¹³, Jean-Philippe Martellosio¹⁴, Laurent Guilleminault¹⁵, Colas Tcherakian¹⁶, Yann Nguyen¹⁷, Claire Demoreuil¹⁸, Philippe Guilpain¹⁹, Giacomo Emmi²⁰ and Benjamin Terrier²¹, ¹Internal medicine departement, Cochin Hospital, Paris, France, ²Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ³Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( ⁷⁵⁰¹⁴ ), Ile-de-France, France, ⁴Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, Paris, France, ⁵Hôpital Foch, Suresnes, France, ⁶Bichat hospital, APHP, Paris, France, ⁷CHU Dijon Bourgogne, Dijon, France, ⁸Internal medicine department, CHU St-Etienne, Saint-Etienne, France, ⁹Internal medicine department, Saint-Luc, Saint-Luc, France, ¹⁰CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France, ¹¹Respiratory Medicine, Université de Rennes ¹, CHU Pontchaillou, Rennes, France, ¹²Tours University Hospital, ³⁷⁰⁰⁰ tours, Ile-de-France, France, ¹³Internal Medicine, CH de Dax, Dax, France, ¹⁴Internal medicine department, CHU Poitiers, Poitiers, France, ¹⁵CHU Toulouse, Toulouse University, Toulouse, France, ¹⁶Pneumology department, Foch, Suresnes, France, ¹⁷Department of Internal Medicine, Beaujon Hospital, AP-HP Nord, Université Paris Cité, Clichy, France, Clichy, France, ¹⁸Internal medicine department, Brest CHU, Brest, France, ¹⁹Internal medicine department, CHU Montpellier, Montpellier, France, ²⁰Department of Medical, Surgery and Health Sciences, University of Trieste, Italy and Clinical Medicine and Rheumatology Unit, Cattinara University Hospital, Trieste, Italy, Trieste, Italy, ²¹Cochin Hospital, Paris, France
Background/Purpose: Glucocorticoid (GC)-dependent asthma and ENT exacerbations may persist in more than half of patients with eosinophilic granulomatosis with polyangiitis (EGPA). Mepolizumab and benralizumab, monoclonal…
Abstract Number: 0716 • ACR Convergence 2025
Utility of Follow-Up Cardiac Magnetic Resonance Imaging In Patients With Eosinophilic Granulomatosis With Polyangiitis
Chelsea Cheng¹, Justine Lafleur-Careau², Navneet Kang¹, Medha Soowamber³ and Christian Pagnoux³, ¹Mount Sinai Hospital, Toronto, Canada, ²Mount Sinai Hospital, Saint-Augustin-de-Desmaures, Canada, ³Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare multisystem disorder characterized by asthma, rhinitis, peripheral blood eosinophilia, and necrotizing vasculitis of small vessels. Cardiac…
Abstract Number: 0715 • ACR Convergence 2025
Supervised machine learning algorithm to identify patients with eosinophilic granulomatosis with polyangiitis in France
Benjamin Terrier¹, Solenne Tauty², Anouar Salhi², Francoise Bugnard², Steve Benard², Vincent Cottin³, Camille Taillé⁴ and Xavier Puéchal⁵, ¹Cochin Hospital, Paris, France, ²Steve Consultants, Lyon, France, ³National Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon ¹, UMR ⁷⁵⁴, ERN-LUNG, Lyon, France, Lyon, France, ⁴Bichat hospital, APHP, Paris, France, ⁵Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( ⁷⁵⁰¹⁴ ), Ile-de-France, France
Background/Purpose: Identifying patients with eosinophilic granulomatosis with polyangiitis (EGPA) in claims databases such as the French National Health Data System (SNDS) is a major challenge…
Abstract Number: 0723 • ACR Convergence 2025
Neutrophil and Eosinophil Extracellular Traps in Eosinophilic Granulomatosis with Polyangiitis: Phenotype-based Characterization and Response to Mepolizumab
Michele Moretti¹, Francesco Ferro², Francesco Pisani³, Elisa Ferrigno³, Gaetano La Rocca⁴, Federica Di Cianni⁵, Rosaria Talarico⁶, Marta Mosca⁷, Chiara Baldini⁷ and Ilaria Puxeddu³, ¹University of Pisa, Rheumatology Unit, Pisa, Italy, ²Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, ³University of Pisa, Pisa, Italy, ⁴University of Pisa, Rheumatology Unit, Pisa, Pisa, Italy, ⁵Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, ⁶Azienda Ospedaliero Universitaria Pisana, Pisa, Pisa, Italy, ⁷University of Pisa, Pisa, Pisa, Italy
Background/Purpose: EGPA variably presents eosinophil (EOS)-related features and vasculitic manifestations. Recent introduction of mepolizumab (MEP) has revolutionized the treatment of EOS manifestations of EGPA. However,…
Abstract Number: 0238 • ACR Convergence 2025
Real-World Effectiveness of Mepolizumab on Gastrointestinal Involvement in Eosinophilic Granulomatosis with Polyangiitis and Hypereosinophilic Syndrome: A Multicenter Retrospective Study
Alessia Gatti¹, Francesca Regola¹, Giulia Fontana², Jacopo Mora², Mario Andrea Piga³, Gianluca Moroncini³, Rossella Acquaviva⁴, Palma Carlucci⁴, Silvia Noviello⁴, Angelo Vacca⁴, Paolo Delvino⁵, Enrico Heffler⁶, Emanuele Nappi⁶, Jakub Moll⁷, Jan Schroeder⁷, Laura Losappio⁷, Federica Davanzo⁸, Roberto Padoan⁹, Paolo Cameli¹⁰, Edoardo Conticini¹¹, Greta Pacini¹², Alvise Berti¹², Lorenzo Vrola¹³, Paola Tomietto¹³, Benedetta Fazzi¹⁴, elena treppo¹⁵, Luca Quartuccio¹⁴, Jan Willem Cohen Tervaert¹⁶, Sabrina Arnold¹⁷, Prof. Dr. med. Peter Lamprecht¹⁸, Florence Roufosse¹⁹, Ilaria Cavazzana¹, Franco Franceschini²⁰, Giacomo Emmi²¹ and Paola Toniati²², ¹Rheumatology and Clinical Immunology Unit – ERN ReCONNET, ASST Spedali Civili of Brescia and University of Brescia, Brescia, Italy, ²Rheumatology and Clinical Immunology Unit – ERN ReCONNET, ASST Spedali Civili and University of Brescia, Brescia, Lombardia, Italy, ³Università Politecnica delle Marche and Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy, ⁴Section of Internal Medicine 'Guido Baccelli', Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari 'Aldo Moro', Bari, Italy, ⁵Rheumatology Unit, IRCCS San Gerardo dei Tintori, Monza, Italy, ⁶Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI) and Personalized Medicine, Asthma and Allergy, IRCCS Humanitas Research Hospital, Milano, Italy, ⁷Division of Allergy and Clinical Immunology, ASST GOM Niguarda, Milano, Italy, ⁸Rheumatology Unit, Department of Medicine DIMED, University of Padua, Padova, Italy, ⁹Rheumatology Unit, Department of Medicine DIMED, University of Padua, Padua, Italy, ¹⁰University of Siena, Siena, Italy, ¹¹Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Italy, Siena, Italy, ¹²Santa Chiara Hospital and University of Trento, Unit of Rheumatology, Trento, Italy, ¹³UCO Medicina Clinica, ASUGI, Cattinara Teaching Hospital, Trieste, Italy, ¹⁴Division of Rheumatology, Department of Medicine (DMED), University of Udine, Udine, Italy, ¹⁵Division of Rheumatology, Department of Medicine, University of Udine, Udine, Italy, ¹⁶University of Alberta, Edmonton, AB, Canada, ¹⁷Department of Rheumatology and Clinical Immunology, University of Lübeck, Lubeck, Germany, ¹⁸University of Lübeck, Lübeck, Germany, ¹⁹Department of Internal Medicine, Hôpital Universitaire de Bruxelles - Erasme, Université Libre de Bruxelles, Bruxelles, Belgium, ²⁰University of Brescia, Brescia, Brescia, Italy, ²¹Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy, ²²Rheumatology and Clinical Immunology Unit – ERN ReCONNET, ASST Spedali Civili of Brescia, Brescia, Lombardia, Italy
Background/Purpose: Eosinophilic gastrointestinal disorders (EGIDs) are a group of disorders characterized by marked eosinophilic infiltration of the gastrointestinal (GI) tract resulting in organ dysfunction and…
Abstract Number: 2532 • ACR Convergence 2025
Temporal arteritis revealing eosinophilic diseases: A multicenter retrospective study, literature review, and combined cluster analysis
Julie Merindol¹, Benjamin Torreau², Matthieu Groh³, Amy Klion⁴, Paolo Delvino⁵, Olivier Espitia⁶, Jean-Benoit Arlet⁷, Sarah Lechtman⁸, Jean-sébastien Allain⁹, Federica Bello¹⁰, Anaelle Boucaud¹¹, Florian Catros¹², Julien Campagne¹³, Anne Coutard¹⁴, Cecile-Audrey DUREL¹⁵, Mikael Ebbo¹⁶, Georgina Espigol-Frigole¹⁷, Giacomo Emmi¹⁸, Yanis Kouchit¹⁹, Guillaume Lefevre²⁰, François Lifermann²¹, PAUL LEGENDRE²², Eric Liozon²³, Francois Maurier²⁴, Sara Melboucy Belhkir²⁵, Sébastien Miranda²⁶, Simon Parreau²³, Paola Parronchi²⁷, Jacques Pouchot²⁸, Vincent Pestre²⁹, Sophie Rosenstingl³⁰, Jan Willem Cohen Tervaert³¹, Odile Souchaud Debouverie³², Xavier Puéchal³³ and Benjamin Terrier³⁴, ¹CHU de Nice, Nice, France, ²Internal Medicine and Immunology, CHU Tours, Tours, France, ³Hôpital Foch, paris, France, ⁴NIAID/NIH, Bethesda, MD, ⁵University of Milano-Bicocca, Monza, Monza and Brianza, Italy, ⁶CHU de Nantes, Nantes, France, ⁷APHP, Paris, ⁸CHU de Nice, Nixe, France, ⁹Scorff-Lorient Hospital, Lorient, France, ¹⁰Université de Florence, Florence, Italy, ¹¹CHU de Tours, Tours, France, ¹²CHI VAL, Ariège, France, ¹³Hopital Robert Schuman, Metz, France, ¹⁴Groupe Hospitalier de Bretagne Sud, Lorient, France, ¹⁵CHU de Lyon, Lyon, France, ¹⁶Internal Medicine, Marseille-APHM, hôpital La Timone, Marseille, France, ¹⁷Hospital Clínic de Barcelona, Barcelona, Spain, ¹⁸Department of Medical, Surgery and Health Sciences, University of Trieste, Italy and Clinical Medicine and Rheumatology Unit, Cattinara University Hospital, Trieste, Italy, Trieste, Italy, ¹⁹CH de Cannes, Cannes, France, ²⁰CHU de Lille, Lille, France, ²¹Internal Medicine, CH de Dax, Dax, France, ²²CH LE MANS, Le Mans, France, ²³CHU de Limoges, Limoges, France, ²⁴HOPITAUX PRIVES DE METZ, Vaux / Frankreich, France, ²⁵CH de Saint Quentin, Saint Quentin, France, ²⁶Internal Medicine, CHU Rouen, Rouen, France, ²⁷CHU de Florence, Florence, Italy, ²⁸AP-HP, Rueil Malmaison, France, ²⁹CH d'Avignon, Avignon, France, ³⁰CH de Compiegne, Compiegne, France, ³¹University of Alberta, Edmonton, AB, Canada, ³²CHU de Poitiers, Poitiers, France, ³³Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( ⁷⁵⁰¹⁴ ), Ile-de-France, France, ³⁴Cochin Hospital, Paris, France
Background/Purpose: Temporal arteritis (TA) classically presents as a large-vessel vasculitis in older adults with cranial ischemic symptoms. However, in younger patients or in the presence…
Abstract Number: 2514 • ACR Convergence 2025
Comparison of Demographics and Outcomes of Inpatient Hospitalization of Severe Asthma Patients with Eosinophilic Granulomatosis with Polyangitis. A Study on the National Inpatient Sample Database
Prakriti Subedi¹, Anil Regmi², Karun Shrestha³, Manoj Ghimire⁴, Sajana Poudel⁵, Kalpana Ghimire¹, Oshna Pandey¹ and Clement Tagoe⁶, ¹St. Barnabas Hospital, Bronx, NY, ²Parkview Health, Fort Wayne, IN, ³St. Barnabas Hospital Internal Medicine Residency, Bronx, NY, ⁴St Barnabas Hospital, BRONX, NY, ⁵Cook County Health, CHICAGO, NY, ⁶Albert Einstein College of Medicine, FRESH MEADOWS, NY
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare vasculitis marked by asthma and eosinophilia, often leading to severe, persistent respiratory symptoms. Unlike severe asthma…
Abstract Number: 2513 • ACR Convergence 2025
Beyond Clinical trials in Eosinophilic Granulomatosis with Polyangiitis: A Systematic Review of effectiveness and safety data derived from real-world evidence of Mepolizumab 300 mg
Iñigo Rúa-Figueroa¹, Beatriz Velasco² and Maria Cid³, ¹Hospital de Gran Canaria Doctor Negrin, Las Palmas GC, Spain, ²GSK, Madrid, Spain, ³Department of Autoimmune Diseases (member of European Reference Network RITA), Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is characterized by systemic necrotizing vasculitis affecting small and medium-sized vessels, and defined by the presence of eosinophilia, extravascular…
Abstract Number: 2504 • ACR Convergence 2025
Variables Associated with In-Hospital Mortality in Adult Eosinophilic Granulomatosis with Polyangiitis from the National Inpatient Sample Database 2017-2021
Anuya Natu¹, Isadora Small², Shilpa Arora³ and Augustine Manadan⁴, ¹John H Stroger, Jr. Hospital of Cook County, Chicago, IL, ²The Latin School of Chicago, Chicago, IL, ³Cook County Hospital, Chicago, IL, ⁴Rush University Medical Center, Chicago, IL
Background/Purpose: Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a rare systemic vasculitis that can lead to significant morbidity and mortality. This study aims to evaluate the…
Abstract Number: 1769 • ACR Convergence 2025
Classification of Relapses of Eosinophilic Granulomatosis with Polyangiitis After Two-Years of Treatment with Anti-Interleukin-5/Receptor Therapy
Christian Pagnoux¹, Arnaud Bourdin², Bernhard Hellmich³, Nader Khalidi⁴, David Jackson⁵, David Jayne⁶, Parameswaran Nair⁷, Ulrich Specks⁸, Benjamin Terrier⁹, Lena Börjesson Sjö¹⁰, Priya Jain¹¹, Aadarsh Lal¹², Sofia Necander¹³, Claire Walton¹⁴, Michael Wechsler¹⁵ and Peter Merkel¹⁶, ¹Mount Sinai Hospital, University Health Network, Toronto, and Canadian Vasculitis Research Network (CanVasc), Toronto, ON, Canada, ²Department of Respiratory Diseases, Montpellier University Hospitals, Arnaud de Villeneuve Hospital, Montpellier, France, ³Klinik für Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie, Medius Kliniken, Akademisches Lehrkrankenhaus der Universität Tübingen, Kirchheim unter Teck, Germany, ⁴Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, Canada, ⁵Guy’s Severe Asthma Centre, Guy's and St Thomas’ NHS Trust, London, and School of Immunology and Microbial Sciences, King's College London, London, United Kingdom, ⁶University of Cambridge, Cambridge, United Kingdom, ⁷Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, ON, Canada, ⁸Mayo Clinic, Rochester, MN, ⁹Cochin Hospital, Paris, France, ¹⁰Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca,, Gothenburg, Sweden, ¹¹BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ¹²Respiratory & Immunology, AstraZeneca, Bengaluru, Karnataka, India, ¹³Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ¹⁴Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ¹⁵Department of Medicine, National Jewish Health, Denver, ¹⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: Results from the ongoing open-label extension (OLE) of the MANDARA trial (NCT04157348) have demonstrated the efficacy of two years of anti-interleukin-5/receptor (anti-IL-5/R) therapies in…

1
2
3
…
5
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].